Orphan Reach is extremely honoured to be part of this crucial Phase II COVID-19 trial at the forefront of clinical research.

We are delighted to be recognised as a specialised company that consistently rises to the challenge of meeting the unmet medical needs of patients. With our focus and expertise in rare diseases, we are confident in our ability to adapt to the challenge ahead. In partnership with Vicore Pharma , our team will work relentlessly as always to accomplish our common goal, to meet the needs of those suffering with COVID-19 in the quickest possible time-frame.

To read the official press release published by Vicore Pharma regarding their submitted Letter of Intent for the Phase II trial to the UK regulatory agency (MHRA), please visit: https://bit.ly/3bDUi00